# Liberum Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liberum-biotech

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.liberumbio.com
- Total disclosed funding: $1.8M
- Latest round: Seed (Jul 24, 2023)
- Investors on record: 3

## About

Based in Toronto, Canada, Liberum Biotech is a biotechnology company focused on advancing protein expression technologies for enzyme and antibody discovery.Liberum Biotech specializes in developing innovative solutions for protein synthesis, having been founded in 2020 in Toronto, Canada. The company was established by Aidan Tinafar, Alexander Klenov, and Ryan Fobel. Since its inception, Liberum has completed 2 investment deals, with the most recent deal occurring on July 24, 2023, during its Seed funding round where it raised USD 1.8 mn, led by TechU Ventures with participation from SOSV and Savantus Ventures. The total amount raised by the company stands at USD 1.8 mn.Liberum Bio specializes in innovative cell-free protein expression reagents and hardware designed to facilitate enzyme and antibody discovery. Its core product offerings include high-yield cell-free reagents and proprietary formulations that enhance protein synthesis capabilities, alongside cartridges equipped with thin-film technology for effective scale-up and purification processes. The company provides protein synthesis as a service through its advanced cell-free systems, targeting businesses engaged in biotechnology, pharmaceuticals, and research institutions that require rapid prototyping and data generation for protein-related applications. By leveraging machine learning integrated with cell-free biology, Liberum Bio aims to deliver actionable insights more efficiently and cost-effectively than traditional methods. The geographical markets for these products extend to North America, Europe, and parts of Asia, catering to a diverse clientele comprised of academic researchers, biotech companies, and pharmaceutical firms.Liberum Bio generates revenue through its specialized products and services structured around B2B transactions. Clients engage with the company primarily through direct service agreements for protein synthesis, alongside the purchase of proprietary reagents and cartridges. These transactions typically involve customized contracts based on the specific needs of the client, allowing for tailored solutions that enhance research and development efforts. Pricing models are aligned with the complexity and volume of the requested services, reflecting the value of high-quality protein expression and discovery capabilities the company provides. This business structure promotes long-term partnerships with clients across various sectors, ensuring a steady revenue stream from both direct sales and ongoing service engagements.In July 2023, Liberum Biotech raised USD 1.8 mn in Seed funding led by TechU Angels to further develop its technology and test unrealized life-saving therapeutics. The company plans to introduce new products that enhance its protein expression capabilities and expand its reach into new geographic markets. Specific targeted markets include Europe and parts of Asia, with plans to solidify these expansions within the next 12 to 18 months.

## Funding rounds

- Seed, Jul 24, 2023, $1.8M — SOSV, TechU Ventures, Savantus Ventures
- Seed, May 13, 2020 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- TechU Ventures (https://capitalatlas.ai/funds/techu-ventures) — Seed
- Savantus Ventures (https://capitalatlas.ai/funds/savantus-ventures) — Seed